RecruitingNot ApplicableNCT07451769

Selective Activation of the Adrenomedullin Receptors in Migraine

Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

Sponsor

Danish Headache Center

Enrollment

26 participants

Start Date

Mar 12, 2026

Study Type

INTERVENTIONAL

Conditions

Pain Brain Diseases Central Nervous System Diseases Migraine Signs and Symptoms Peptides Adrenomedullin Neuropeptides

Summary

Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adrenomedullin and Placebo for people with adrenomedullin, brain diseases, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.